Combining the cannabinoid cannabinol (CBN) with the breast cancer drug exemestane may significantly improve treatment ...

The FDA will decide whether to approve a once-daily, 25 mg oral formulation of semaglutide (Wegovy) by the end of 2025. If ...

Balancing estrogen isn’t just about cutting soy—it’s about strategic, science-backed foods that go beyond the basics ...

Interest in developing selective inhibitors has produced tool compounds for the inactivation or degradation of AKR1C3 with varying degrees of selectivity among the 14 known AKR proteins. Selectivity ...

It is taken with an aromatase inhibitor to reduce oestrogen levels. Common side effects include fatigue, anaemia, infection risk, rash, dizziness, and gastrointestinal symptoms. NICE said that ...

Sanofi will halt the development of its oral tumour necrosis factor (TNF) inhibitor balinatunfib as a monotherapy after it failed to reach the primary endpoint in a Phase II trial. Preliminary ...

Led by AbbVie’s Humira, biologic TNF inhibitors transformed the treatment of autoimmune diseases over the past 20 years. However, the biologic modality can cause adverse effects and loss of ...

NEW YORK – The National Institute for Health and Care Excellence (NICE) is recommending Novartis' Kisqali (ribociclib) plus an aromatase inhibitor for certain patients with early-stage breast cancer ...

Today, the National Institute for Health and Care Excellence (NICE) published its preliminary optimised recommendation 1 for ribociclib to be used as adjuvant treatment in combination with an ...